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Abstract 
Among the causative factors for acute pancreatitis, adverse drug reactions are considered to 
be rare. The diagnosis of drug-induced pancreatitis (DIP) is challenging to establish, and is 
often underestimated because of the difficulties in determining the causative agent and the 
need for a retrospective re-evaluation of the suspected agent. We present the case of an 
80-year-old woman who presented with complaints of abdominal pain. Her medications 
included methimazole (MMI) which she had been on for the past 3 months. Computed 
tomography of her abdomen showed peripancreatic fat stranding with trace amount of 
surrounding fluid, along with amylase and lipase levels suggestive of acute pancreatitis. In 
the absence of classical risk factors for acute pancreatitis, a diagnosis of DIP secondary to 
MMI use was made. Withdrawal of the drug from her medication regimen was accompanied 
by relief of symptoms and resolution of clinical evidence of pancreatitis. The aim of this 
paper is to report only the fourth case of MMI-induced pancreatitis in the published 
literature, and to illustrate the significance of an appropriate and timely diagnosis of DIP. 
 
Introduction 
The incidence of acute pancreatitis is increasing worldwide, and it now ranks as the 
second most common inpatient gastrointestinal diagnosis in the United States. The 
economic burden of acute pancreatitis is tremendous, with an estimated 2.5 billion 
dollars spent annually on inpatient and outpatient medical services directed towards 
the disorder. In 2000 alone, an estimated 2,834 deaths in the United States occurred 
from acute pancreatitis, making it the 14th most common cause of death due to 
gastrointestinal disease [1]. While alcohol and gallstones account for the most  
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important etiologic factors for acute pancreatitis, the impact of other agents such as 
prescribed drugs is being increasingly appreciated. 
The incidence of drug-induced pancreatitis (DIP) is generally estimated from case 
reports or as a result of studies designed and conducted for other purposes. DIP has a 
clinical manifestation similar to acute pancreatitis from other causes, but the diagnosis 
is difficult to establish, mainly stemming from the absence of cause-specific diagnostic 
tests. The diagnosis of DIP usually hinges on four criteria: (1) acute pancreatitis occurs 
during the administration of the drug; (2) all other common causes of acute 
pancreatitis are excluded; (3) symptoms of acute pancreatitis disappear after drug 
withdrawal; (4) symptoms recur after re-challenge of the suspected drug [2]. 
Methimazole (MMI), which belongs to the imidazole class of antithyroid medications, 
has long been the mainstay of therapy for patients with Grave’s disease and other 
hyperthyroid states. Although known to be one of the most reliable methods of 
achieving the euthyroid state, the medication does not come without a myriad of 
adverse effects. The most common side effects reported from use of MMI include fever, 
pruritus, and nausea. Less frequently encountered adverse effects such as 
granulocytopenia, drug-induced lupus, and severe arthralgia should be suspected in 
patients with such abnormities while on MMI. DIP from MMI use is rare, with only three 
known cases reported to date, although the true incidence of MMI-induced acute 
pancreatitis is unclear [3–5]. 
The true incidence of DIP remains largely unknown. There has been considerable 
underreporting of DIP in particular due to the fact that the index of suspicion for DIP is 
lower compared with drug-induced liver disease and other potential medication side 
effects. Also, milder cases evident by significant but not critical elevations of serum 
amylase and lipase are often missed by clinicians, unless heightened suspicion of DIP is 
present. It often takes an astute physician to recognize DIP, given the differences in 
latent period between the time of drug exposure and the time of development of acute 
pancreatitis. Unfortunately, many cases of DIP are erroneously classified as due to 
alcohol or gallstones. Treatment often includes making the patient nil per os and thus 
inadvertently discontinuing a possible offending medication and missing the 
opportunity to diagnose DIP. Finally, the true incidence of DIP remains largely 
unknown because often when a case of DIP is correctly identified, it is seldom reported 
[6, 7]. 
Here we present the case of a patient who presented with abdominal pain and was 
diagnosed with MMI-induced pancreatitis.  
Case Report 
An 80-year-old Caucasian woman presented to the emergency room with complaints of epigastric 
pain. She described the pain as being sharp, continuous for the past 2 months, progressively 
increasing in intensity, worsened with food intake and associated with nausea. She denied any fever, 
vomiting, diarrhea, constipation, blood per rectum, weight loss, sick contacts or any recent travel. She 
also denied any yellowing of the eyes, joint pains or rashes on her skin. Her past medical history was 
significant for hypertension and hyperthyroidism which had been diagnosed 3 months prior. Her 
home medications included aspirin 81 mg and MMI 10 mg. She did not have a history of drug allergies. 
She denied the use of tobacco, alcohol, illicit drugs, and the use of any supplemental tablets. Family 
history was unremarkable including the absence of any gastrointestinal disorders.  
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On physical examination, the patient appeared mildly anxious but in no apparent distress. Her vital 
signs were stable. Examination of her abdomen revealed mild epigastric tenderness without rebound 
tenderness, guarding or rigidity. There was neither abdominal distension nor organomegaly, and 
bowel sounds were noted to be normal. A complete blood count and basic metabolic profile were 
within normal limits. Liver-related tests revealed alanine aminotransferase of 40 IU/l, aspartate 
aminotransferase of 55 IU/l and alkaline phosphatase of 133 IU/l. Also remarkable was a serum 
amylase level of 371 IU/l, a lipase level of 581 IU/l and a lactate dehydrogenase level of 251 IU/l. 
Cardiac enzymes and a lipid panel were within normal limits. An abdominal ultrasound was 
performed which showed no evidence of cholelithiasis. Computed tomography of her abdomen 
revealed peripancreatic fat stranding with trace amount of surrounding fluid suggestive of acute 
pancreatitis (fig. 1). There was no evidence of biliary duct dilatation. A provisional diagnosis of DIP 
due to MMI use was made in the absence of other risk factors for acute pancreatitis. She was started 
on intravenous fluids and given supportive therapy. MMI was discontinued from her drug regimen. 
After 4 days of conservative management, the patient showed clinical improvement with resolution of 
her abdominal pain and normalization of lipase levels. She was later discharged from the hospital and 
has been doing well since. The patient refused a re-challenge with MMI.  
Discussion 
Drugs are seldom considered to cause acute pancreatitis, although the World Health 
Organization (WHO) database listed 2,479 episodes suspected of being caused by 525 
different drugs between 1968 and 1993 [8]. It is difficult to determine the true 
incidence of DIP due to the lack of consistent reporting and lack of large prospective 
trials. Most information has been communicated in the form of single case reports 
either reported to local drug safety committees or published as case reports or letters 
to the editor in peer-reviewed journals. Summaries of the available data suggest that 
between 0.1 and 2% of cases of acute pancreatitis may be drug-induced, with a 
retrospective case study from the Czech Republic finding the incidence rate to be as 
high as 5.3% [2, 9]. 
Epidemiological data suggest that certain populations may be at higher risk for 
DIP, including pediatric patients, the elderly, patients with advanced human 
immunodeficiency virus (HIV) infection, patients with inflammatory bowel disease, 
and patients prescribed polypharmacy. The increased risk in children may be conferred 
as traditional risk factors for pancreatitis such as alcohol abuse are rarely present. In 
the elderly, polypharmacotherapy and resulting drug interactions may increase the risk 
of DIP. In patients with advanced HIV infection, the incidence of DIP has been reported 
to be as high as 14%. Patients with advanced HIV infection may be more susceptible to 
DIP due to various factors, including impaired balance of CD4 and CD8 cells, increased 
rate of exogenous and nosocomial infections, and polypharmacy with antiretroviral 
medications. Those with inflammatory bowel disease are believed to suffer from an 
increased risk for DIP due in part to their underlying disease, rather than medications 
alone. For example, acute pancreatitis as an adverse reaction to azathioprine is rarely 
noted if used for the treatment of conditions other than inflammatory bowel disease, 
such as rheumatoid arthritis, systemic lupus erythematosus or after kidney 
transplantation. This supports the hypothesis that inflammatory bowel disease in itself 
bears an increased risk for acute pancreatitis that is independent of the medication 
used for therapy, or that patients with inflammatory bowel disease have a predilection 
for azathioprine-induced pancreatitis. The effect of polypharmacy and combination 
drug therapy on the increased incidence of acute pancreatitis was highlighted in a 
case-control study from Denmark. One example given in that study described that the  
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risk of developing acute pancreatitis from metronidazole was increased 8-fold if 
patients received metronidazole in combination with other drugs used to eradicate 
Helicobacter pylori, such as proton pump inhibitors and amoxicillin [9, 10]. 
The pathophysiologic mechanism of DIP is not well established for many drugs 
including MMI; however the literature suggests that a few medications do indeed have 
a distinct mechanism for causing DIP. A direct toxic effect to the pancreas may explain 
the sequence of events in drugs like metronidazole, which is a medication known to 
diffuse into the pancreas. In other drugs such as tetracycline, the pathophysiology may 
involve accumulation of toxic metabolites in the pancreas, resulting in acute 
inflammation. The putative mechanisms by which codeine causes acute pancreatitis 
have been postulated to be due to sphincter of Oddi spasm, resulting in eventual 
pancreatic inflammation. The effect of estrogen supplementation on the pancreas may 
be indirect with alterations in the plasma triglyceride level possibly contributing to 
development of acute pancreatitis. In the case of chlorothiazide-induced acute 
pancreatitis, the potential mechanisms include thiazide-induced hyperparathyroidism, 
hyperlipidemia, hypercalcemia or hypotension, resulting in pancreatic ischemia. 
Angiotensin-converting enzyme inhibitors (ACEIs) are well documented to potentially 
result in DIP, as angioedema of the pancreatic duct due to an interaction with the 
kallikrein-kinin system could explain some cases. Another theory suggests that ACEIs 
disturb the pancreatic microcirculation and ductal anion secretion by changing the 
physiology of the pancreatic renin-angiotensin system. Overdose of medications not 
classically associated with DIP has also been reported, including paracetamol, 
erythromycin, carbamazepine and codeine [2, 9, 11]. 
The diagnosis of DIP can be challenging for clinicians. If evidence of acute 
pancreatitis has been established, common etiologies such as gallstones and alcohol 
abuse need to be excluded. A careful review of all medications taken by the patient 
should be recorded, and if the patient takes any drug suspected to cause pancreatitis, 
this should be discontinued if safely possible. If it is not possible to stop the medication, 
it should be substituted for an alternative medication, if possible from another class of 
substances. If symptoms stop after the drug has been discontinued, a diagnosis of DIP is 
probable. Re-exposure to the medication should only be considered if the potential 
benefits outweigh the risks. Fig. 2 summarizes the approach to a case of DIP [6]. 
The most extensive overview of DIP was published by Trivedi et al. [6], in which all 
reported cases of DIP via the National Library of Medicine/PubMed from 1966 to 2004 
were reviewed. In this review, medications implicated in cases of DIP were classified 
based on incidence and medication re-challenge data. Class I medications were defined 
as those implicated in greater than 20 cases of acute pancreatitis, with at least one 
documented case following re-exposure. Class II medications were involved in more 
than 10 but fewer than 20 cases, with or without a positive re-challenge. Class III 
medications included all other drugs reported to be associated with DIP. Table 1 lists 
the drugs reported to be class I medications according to the classification method used 
by Trivedi et al. [6]. As there are less than 10 cases of MMI-induced pancreatitis 
reported, this drug would be considered as class III in regards to the relative risk for 
DIP. 
Karch and Lasagna [12] classified drugs based on evidence for adverse drug 
reactions into definite, probable and possible causes. According to this classification,  
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the causality was definite if a drug reaction followed the administration of the drug 
in a temporal sequence and in a known response pattern. Moreover this should be 
confirmed by cessation of the drug (de-challenge) with reappearance of symptoms 
upon repeated exposure to the drug (re-challenge). A drug reaction was probable if 
the reaction followed administration of the drug in a reasonable temporal sequence 
with symptoms abating on de-challenge. Re-challenge was never attempted but the 
symptoms could not be explained by the known characteristics of the patient’s clinical 
state. Possible cause, the weakest causality defined, was if the drug reaction followed a 
temporal sequence from administration of the drug, but the symptoms could also be 
explained by the patient’s clinical state or other modes of therapy administered to the 
patient.  
Vinklerova et al. [2], Andersen et al. [7], Barreto et al. [11], Lankisch et al. [13] 
and Eland et al. [14] suggest that the incidence of DIP ranges from 0.1 to 5.3%. In 
these studies, 10 different drugs were found to have a definite causality with acute 
pancreatitis (table 2), with the time relationship between intake of the drug and onset 
of acute pancreatitis varying from 1 day to 17 years. Among the drugs with a definite 
causality of DIP, death was reported only with valproate and azathioprine. Some of the 
drugs found to have a probable or possible causality to acute pancreatitis included 
alendronate, allopurinol, doxycycline, famotidine, hydrochlorothiazide, ibuprofen, 
lithium, ramipril and rifampin. 
In conclusion, it is possible to state that DIP is not a negligible disease. The diagnosis 
seems to be underestimated because of the difficulties in determining the causative 
agent and need for a retrospective re-evaluation of the suspected causative factors. This 
was highlighted by Spanier et al. [15] who in a recent multicenter observational study 
reported that in 4.8% of patients a diagnosis of DIP was missed, possibly leading to the 
patient’s detriment. Despite the moderate severity of DIP, all patients with acute 
pancreatitis of unknown etiology should be carefully questioned regarding current 
medication use. Clinicians should be cognizant of the rare but relevant incidence of 
MMI-induced pancreatitis, allowing for timely diagnosis and management of DIP. Once 
identified, offending agents should be discontinued to reduce further episodes of acute 
pancreatitis. 
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Table 1. Class I drugs showing the number of cases following 
re-exposure as reported by Trivedi et al. [6] 
            Drugs  Reported 
cases 
Cases following 
re-exposure 
            Didanosine   883  09 
Asparaginase  177  02 
Azathioprine  086  16 
Valproic acid  080  11 
Pentavalent antimonials  080  14 
Pentamidine  079  02 
Mercaptopurine  069  10 
Mesalamine  059  12 
Estrogens  042  11 
Opiates  042  05 
Tetracycline  034  02 
Cytarabine  026  04 
Steroids  025  01 
Sulfamethoxazole/trimethoprim  024  01 
Sulfasalazine  023  05 
Furosemide  021  03 
Sulindac  021  08 
             
 
Table 2. Drugs with a definite causality as reported in several case studies [2, 7, 11, 13, 14] 
                    Drugs  Cases  Definite  Death  Reported time intervals 
                    Azathioprine  19  7  1  10 days to 13 months 
Cimetidine  01  1  0  5 days 
Codeine1  06  2  0  1 day to 3 months 
Interferon α  03  1  0  15 weeks2 
Methyldopa  02  2  0  2 weeks 
Metronidazole  01  1  0  1 day 
Phenylbutazone/oxyphenbutazone  02  1  0  21 days2 
Statins3  03  1  0  2 months to 1 year 
Valproate  06  2  2  1.5–17 years 
5-ASA4  22  5  0  5–28 days 
                    1 In the 2 cases of definite association reported by Barreto et al. [11], a combination medication of codeine 
and ibuprofen was used. 2 Time intervals were only reported in the study by Eland et al. [14]. 3 Definite 
association was seen only with simvastatin as reported by Andersen et al. [7]. 4 Definite association was 
reported for mesalazine (4 cases) and olsalazine (1 case). 
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Fig. 1. Computed tomography showing the pancreas (arrow) with trace amounts of surrounding fluid 
and peripancreatic fat stranding, suggestive of acute pancreatitis. 
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Fig. 2. Algorithm for the management of DIP. 
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